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Abstract
Background In Qatar, the National Vision 2030 and the National Health Strategy 2018–2022 articulate the need to improve 
healthcare delivery by better utilisation of the skilled workforce. In this regard, pharmacy practice is rapidly advancing and 
several extended pharmacy services are now available in institutionalised settings. Objective This study aimed to determine 
health-related stakeholders’ perceptions of current clinical pharmacy services in Qatar, and the potential development and 
implementation of further patient-centred roles. Setting All major organisations and institutions relating to the practice, 
education, regulation, and governance of pharmacy in Qatar. Method Qualitative, face-to-face semi-structured interviews 
were conducted with individuals in key strategic positions of policy development and influence (i.e. health-related academic 
leaders, healthcare policy developers, directors of medicine/pharmacy/nursing, and patient safety leaders). Participants were 
recruited via a combination of purposeful and snowball sampling, until the point of data saturation was reached. The interview 
guide was grounded in the Consolidated Framework for Implementation Research domains of innovation characteristics, 
outer and inner setting, characteristics of individuals, and implementation process. The interviews were digitally recorded, 
transcribed and independently analysed by two researchers using the Framework approach. Main outcome measure Percep-
tions of stakeholders regarding current and potential for future clinical pharmacy services in Qatar. Results Thirty-seven 
interviews were conducted with stakeholders of policy influence in healthcare. The interviewees reported a variety of clini-
cal pharmacy services available in Qatar, which they perceived as positively impacting patient care outcomes, pharmacists’ 
professional autonomy, and the healthcare system in general (innovation characteristics). However, they perceived that these 
services were mainly performed in hospitals and less in community pharmacy setting (inner setting) and were undervalued 
by patients and the public (outer setting). Expansion of pharmacists’ clinical activities was supported, with recognition of 
facilitators such as the skillset and training of pharmacists, potential time release due to automation and well-considered 
implementation processes (characteristics of individuals, inner setting, process). Conclusion Health-related stakeholders 
in Qatar have positive perceptions of current clinical pharmacy services and support the expansion of pharmacist’s roles. 
However, service development needs to consider the issues of patient and public awareness and initially target institution-
alised healthcare settings.
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Impacts on practice
• In Qatar, pharmacy practice is rapidly advancing and sev-
eral extended clinical pharmacy services are now avail-
able in institutionalised healthcare settings.
• However, limited evidence is available to explore how 
key health-related stakeholders perceive these services 
including the potential development and implementation 
of new patient-centred pharmacist’s roles.
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• Findings of this research could facilitate cognitive phar-
maceutical service development and better provision of 
patient-centered care, which could be transferrable to 
other countries, especially from the context of the Mid-
dle East.
Introduction
The evolution from product focused pharmacy services to 
more patient-centred pharmacy services was articulated in 
World Health Organization (WHO) policy documents advo-
cating better use of pharmacists’ skills to improve health 
care [1–3]. Similarly, the International Pharmaceutical Fed-
eration (the global body representing pharmacy, pharmaceu-
tical sciences and pharmaceutical education) advocates the 
systematic development and implementation of more clinical 
patient-centred and outcomes-oriented services [4, 5].
Several countries have well-developed clinical pharmacy 
services which are part of routine practice. For instance, 
in the United Kingdom (UK), clinical pharmacy services 
have evolved from rarely providing therapeutic drug moni-
toring and medication history-taking to the introduction of 
supplementary prescribing in 2003 and independent pre-
scribing in 2006 [6, 7]. The majority of literature evaluating 
pharmacist prescribers’ practice demonstrates safety, the 
achievement of clinical outcomes comparable to physicians 
[8, 9] and acceptability by a range of key health stakehold-
ers [10, 11]. In 2015, the UK launched an ambitious plan 
aiming to embed clinical pharmacists within general medi-
cal practices [12, 13]. An independent evaluation based on 
pilot data from England confirms the significant contribution 
to patient safety, supporting long-term condition manage-
ment, and improving medication knowledge within the team 
[14]. Similar positive results have been reported in Scotland, 
where pharmacists are now practising within one-third of 
general medical practices [15].
Over the past decade, Qatar has taken steps to transform 
its healthcare system. The Qatar National Vision 2030 aims 
to “transform Qatar into an advanced country by 2030, 
capable of sustaining its own development and provid-
ing for a high standard of living for all of its people for 
generations to come” by “balancing the accomplishments 
that achieve economic growth with the human and natural 
resources” [16]. To realise the ambitions of the National 
Vision for a healthy population, the National Health Strat-
egy was launched in 2011 [17]. Six projects were initiated, 
one of which aimed to strengthen the role of pharmacists 
in supporting patients, as well as improving the quality of 
healthcare system by making it more accessible and less 
costly. Recently, the Ministry of Public Health reinforced 
the shift in care provision from secondary and tertiary care 
to primary care in an updated National Health Strategy 
2018–2022, “Our Health, Our Future: Improved health for 
Qatar’s population, meeting the needs of existing and future 
generations” [18].
Healthcare in Qatar is provided through government-
funded and private-provided secondary and tertiary institu-
tions, government-funded primary healthcare centres and 
private sector centres (ambulatory care), and community 
pharmacies (Fig. 1) [19].
Hamad Medical Corporation (HMC) is the largest pro-
vider of healthcare in Qatar, and is regarded as one of the 
leading hospital services providers in the Middle East 
region. HMC manages 12 hospitals—nine specialist hospi-
tals and three community hospitals—as well as the National 
Ambulance Service and home and residential care services 
[21]. In 2016, HMC became the first healthcare system 
across the globe to have all its hospitals accredited by Joint 
Commission International (JCI) under the Academic Medi-
cal Center accreditation program [21].
Pharmacy practice in Qatar has advanced in recent years 
due to multiple factors including the establishment of the 
first national college of pharmacy in 2007 [22]. As at 2013, 
the number of pharmacists registered in Qatar was 1023 in 
the public and 991 in the private sectors giving an estimated 
1.01 pharmacists per 1000 population [23, 24]. There is 
some evidence that pharmacy services are evolving toward 
clinical, patient-centred roles [25]. HMC has implemented 
a pharmacist-led anticoagulation clinic, with initial positive 
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Fig. 1  Healthcare system in Qatar [20]
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findings for clinical outcomes of time in therapeutic range 
(TTR), percentage of visits within therapeutic range and 
reduced percentage of visits with extreme subtherapeutic 
international normalized ratio (INR) [22, 26]. Therefore, 
pharmacy practice is rapidly advancing and several extended 
pharmacy services are now available in institutionalised 
settings in Qatar. There, however, remains potential for 
expanding further clinical pharmacy services to all sectors of 
practice. Obtaining the perceptions of key decision-makers 
(stakeholders) would facilitate plans for expansion.
Aim of the study
This study aimed to determine health-related stakeholders’ 
perceptions of current clinical pharmacy services in Qatar, 
and the potential development and implementation of further 
patient-centred roles.
Ethics approval
Ethical approval was granted by Robert Gordon Uni-
versity School of Pharmacy and Life Sciences Research 
Ethics Committee (Approval reference S64), Ministry of 
Public Health Ethics Committee, Hamad Medical Corpo-
ration Medical Research Committee (Approval reference 
MRC0449/2017), and Qatar University Institutional Review 
Board (Approval reference QU-IRB 772-E/17).
Methods
Study design
This study utilised a qualitative approach of semi-structured 
interviews with key stakeholders. A qualitative methodology 
was selected to generate in-depth, rich data allowing detailed 
description and understanding of perceptions around clinical 
pharmacy practice in Qatar [27].
Setting
Data generation took place across all major organisations 
and institutions relating to the practice, education, regula-
tion, and governance of pharmacy practice in Qatar. These 
comprised of the Ministry of Public Health; primary, sec-
ondary and tertiary healthcare institutions; community phar-
macies; and all healthcare academic institutions providing 
pharmacy, medical, nursing, and pharmacy technician edu-
cation programmes.
Inclusion and exclusion criteria
The intention was to generate data representing all key stake-
holder groups, with policy influence relating to the develop-
ment, implementation and evaluation of clinical models of 
care. The groups targeted were individuals in key strategic 
positions of policy influence (i.e. health-related academic 
leaders, healthcare policy developers, directors of medicine/
pharmacy/nursing, and patient safety leaders). Members of 
the research team based in Qatar, who might have satisfied 
the above criteria, were excluded from the study.
Sampling and sampling approach
The sampling frame included all individuals meeting the 
inclusion and exclusion criteria. The names and contact 
details of all potential participants were collated by the 
research team members using their professional networks. 
Purposive sampling was employed to capture those individu-
als who were most likely to contribute to the achievement of 
the research objectives. Snowball sampling was also utilised 
to ensure that no key individuals had been omitted by ask-
ing each interviewee to recommend others that they thought 
were important to include. Sample size was determined to 
achieve data saturation according to the steps outlined by 
Francis et al. [28] Five members from each professional 
group were interviewed as the initial analysis sample. This 
sample was believed to represent adequate diversity based 
on the participants’ professions. Afterwards, one additional 
interview was performed for each professional group before 
the stopping criterion was tested. Responses were coded and 
analysed independently by two research team members in 
order to confirm that data saturation was achieved.
Development of interview guide
The semi-structured interview guide was constructed based 
on a review of the published literature on pharmacy practice 
and grounded in the Consolidated Framework for Implemen-
tation Research (CFIR) [29]. This theoretical framework was 
used to ensure that all relevant implementation factors that 
can determine the success or failure of any innovation are 
deliberated. The guide was developed and mapped against 
the five main domains of CFIR: innovation characteristics 
(of the intervention being implemented into a particular 
organisation), outer setting (i.e. economical, political, and 
social context within which an organisation resides), inner 
setting (i.e. structural, political, and cultural context through 
which implementation process will proceed), characteristics 
of individuals (who will enact the intervention), and pro-
cess (of implementation) [29]. The interview guide included 
questions related to participants’ awareness of current clini-
cal roles performed by pharmacists in Qatar, their views on 
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the efficiency of these services and any potential roles phar-
macists in Qatar can perform in the future. The guide was 
reviewed for dependability, which is the degree to which 
different researchers are able to produce the same data [30], 
by members of the research team prior to piloting with five 
academic and practice-based stakeholders. This pilot process 
did not lead to any major changes to the guide. Pilot inter-
views were not included in the dataset.
Data generation
All potential participants were e-mailed the information leaf-
let, with a reminder sent 2 weeks later if no response had 
been received. The interviews were conducted from April 
to August 2017 by one of the research team members (TJ) 
who was trained in conducting qualitative research. Writ-
ten, informed consent was obtained from all research par-
ticipants before commencing. Interviews, of approximately 
45–60 min, were audio-recorded and later transcribed by 
TJ and reviewed for accuracy by DS. All interviewees were 
offered the opportunity to review the transcripts to promote 
credibility and dependability [30].
Data analysis
Thematic analysis was conducted using the framework 
approach following the steps outlined by Ritchie and Spen-
cer [31]. All interviews were input into  NVivo® software 
then initially coded by TJ based on the different constructs 
of the CFIR before being examined for further sub-themes 
within each construct. Afterwards, the emerging themes 
were reviewed against the original data then indexed and 
refined. The analysis was reviewed by another team mem-




Out of 74 stakeholders invited, 37 interviews were con-
ducted to reach data saturation in each stakeholder group 
giving representation of all practice settings (Table 1).
Key themes that emerged from the interviews
Themes which emerged during the interviews were mapped 
to the different CFIR domains. The major themes frequently 
highlighted by interviewees are described in more details 
below while the rest are summarised in Table 2. There were 
no marked differences in responses across the professional 
groupings.
Interviewees noted a significant evolution in clinical 
pharmacy services in Qatar, illustrated by the continuous 
implementation of new services such as the pharmacist-
run anticoagulation clinic with advantages to patients and 
pharmacists themselves (CFIR domain: innovation char-
acteristics). These developments were perceived as being 
carefully planned with clear communications, guidelines, 
and monitoring processes (CFIR domain: process). The 
interviewees perceived that these services were mainly per-
formed in hospitals and less in community pharmacy setting 
(CFIR domain: inner setting). However, a lack of patient 
and public awareness regarding clinical pharmacy activi-
ties was also highlighted (CFIR domain: outer setting). In 
addition, some stakeholders reported that the majority of 
clinical pharmacy services were performed exclusively in 
hospitals with community pharmacy setting mainly focused 
on traditional pharmacist’s product-oriented role of drugs 
dispensing. Nevertheless, the interviewees highlighted 
the potential for further development, aligned to the Qatar 
National Vision and supported by healthcare leaders (CFIR 
domain: inner setting). They also commented on the quality 
of the education and training of pharmacists and the strict 
licensing requirements to practice in Qatar (CFIR domain: 
characteristics of individuals).
Given that most discussion (based on counts and depth 
of discussion) centred on specific CFIR domains and con-
structs, these are considered in more detail. These were: 
innovation source (perception of key stakeholders about 
Table 1  Characteristics of included stakeholders according to prac-
tice setting
*Some held multiple roles within their organisation
Stakeholders’ category Setting: number of participants*
Academic leaders Medicine: 2
Pharmacy and Pharmacy technician: 5
Nursing: 2












Nursing practice leaders Secondary care: 1
Tertiary care: 5
Corporate/Ministry: 3
Patient safety advocates Primary care/Community: 1
Secondary care: 1
Tertiary care: 4
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whether the intervention is externally or internally devel-
oped); relative advantage (stakeholders’ perception of the 
advantage of implementing the intervention versus an alter-
native solution); design quality and packaging (perceived 
excellence in how the intervention is bundled, presented, 
and assembled); structural characteristics (the social archi-
tecture, age, maturity, and size of an organization); and com-
patibility (the degree of tangible fit between meaning and 
values attached to the intervention by involved individuals, 
how those align with individuals’ own norms, values, and 
perceived risks and needs, and how the intervention fits with 
existing workflows and systems).
Innovation characteristics
In terms of the innovation of clinical pharmacy practice, 
there was recognition that this was developing at pace, par-
ticularly within HMC. There was description of the clinical 
pharmacy service in general and exemplified through spe-
cialist activities such as the pharmacist-led anticoagulation 
clinic.
1. Innovation source
There was recognition that the anticoagulation ser-
vice had developed significantly in recent years. This was 
expressed by participants from all stakeholder groups.
The clinical pharmacists’ role has developed quite sig-
nificantly in recent years like, for example, in [Name] 
Hospital there is the anticoagulation clinic that is run 
by pharmacists.
Academic Leader 1
The clinical service had extended to allow dose 
adjustment.
We call it the anticoagulation clinic where the clini-
cal pharmacists are on the front line, meeting the 
patients…checking the INR and then adjusting the 
dose, so they make the decision.
Medical Practice Leader 5
There was recognition of other HMC clinical services.
Also in clozapine clinic in mental health, there is a 
direct contact with the patient for monitoring the side 
effects and recording if require changing the dose…
Pharmacy Practice Leader 4
2. Relative advantage
Clinical practice was perceived to bring advantages 
including professional autonomy, which was considered 
important to further developments.
… it will give you more confidence in what you are 
doing, your clinical skills, would help increase the 
trust that is given to the pharmacists and maybe help 
them gain more roles in the future.
Academic Leader 6
There were also examples of positive feedback from 
patients at HMC.
Generally our feedback with like warfarin clinics and 
such that we have is very positive… patients don’t wait 
for months to get an appointment.
Healthcare Policy Leader 2
This clinical service was also reported to reduce pressure 
on physicians.
The most important advantage I see from the side of 
physicians is that it will free their time to do more 
skilled work.
Academic Leader 6
There was also the view that patient health outcomes were 
improving.
We can see definitely that the anticoagulation out-
comes have been better with those monitored by phar-
macists.
Academic Leader 6
3. Design quality and packaging
Mandatory continuing professional development for phar-
macists was considered a positive development, contributing 
to the quality of services.
I think they are efficient. They keep continuous educa-
tion so they have weekly sessions so they are updating 
themselves.
Healthcare Policy Leader 1
Furthermore, those involved in the delivery of new and 
specialised services had to undertake further education and 
training.
It is a condensed course that focuses on anticoagula-
tion, how to dose, what are the guidelines available 
and the pathophysiology.
Pharmacy Practice Leader 3
While these developments were in HMC settings, it was 
highlighted that they could also be in others such as in pri-
mary healthcare centres.
They don’t have it in primary healthcare, the warfarin 
clinic. But if the volume of patients increase, it can be 
in primary healthcare, why not?
Medical Practice Leader 5




Many participants highlighted that while the public sec-
tor was highly regulated with focus on quality of care, the 
private sector was profit-oriented.
The public sector I think it is more structured 
because they are accredited… but in private, noth-
ing. They don’t have the policies, they don’t have 
guidelines, they are more or less looking for money.
Healthcare Policy Leader 3
There were contradictory views around the influence 
and power of the medical profession around these develop-
ments in clinical pharmacy practice.
It is still completely physician driven. There is still 
a hierarchy.
Academic Leader 8
In the cancer centre they have a very intimate col-
laboration with them [physicians] and communica-
tion and they really are valued [as an] equivalent 
member of the team. There is no hierarchy.
Medical Practice Leader 1
One overwhelming theme was that clinical pharmacy 
practice varied greatly with setting. There was recognition 
that HMC was much further advanced than other settings.
As for practice, hospitals are better than community 
since community is not well developed because it 
lacks assessment and clinical practice.
Pharmacy Practice Leader 6
In primary healthcare centres, they are developing 
now, they are in a better position if you compare 
them to the community pharmacists. But I have to 




There was some appreciation that the clinical phar-
macy services in HMC could be benchmarked to practice 
in western countries.
I left the UK thinking that I had a very good phar-
macy service. I have come to Qatar and there is a 
better pharmacy service here in my view.
Healthcare Policy Leader 5
The level of technology and automation available within 
HMC was considered a positive facilitator of development.
The level of automation that goes into packages like 
Cerner is clearly already demonstrating that pharma-
cists can take on a more assertive role on behalf of the 
patients to protect their safety…
Healthcare Policy Leader 4
While the clinical anticoagulation clinic was well-estab-
lished, it was noted that this took time, with acceleration 
once physicians had evidence of positive outcomes.
At the beginning, when they don’t have much experi-
ence with it, they may be a little bit suspicious… but 
then after a while, after they saw our abilities and 
how really the patients have been stable and moni-




Key stakeholders in Qatar perceived clinical pharmacy ser-
vices as having a positive impact on patients’ outcomes, 
pharmacists’ professional autonomy, and the overall health-
care system. However, interviewees did highlight differences 
in the extent of the implementation with tertiary and second-
ary public care (mainly HMC) being the most advanced. 
Interviewees perceived a lack of awareness of the extent of 
knowledge, training and practice of pharmacists in Qatar 
and that pharmacists were undervalued by patients and the 
public. There was potential to advance clinical pharmacy 
services, with recognition of facilitators such as the skillset 
and training of pharmacists, potential time release due to 
automation and well-considered implementation processes.
Pharmacists’ contribution to the healthcare system, the 
multidisciplinary team and thus patient care, aligns to the 
aspirations of the Qatar National Vision [16], its associ-
ated health strategies [17, 18] and international efforts for 
advancing patient-centred pharmacy practice [1–5].
Several aspects of healthcare setting emerged in this study 
as being key to the development and perceived success of 
patient-centred clinical pharmacy services, relating to CFIR 
domains of innovation characteristics, inner setting, outer 
setting, characteristics of individuals and process. This is 
not unique to Qatar, with the WHO and the International 
Pharmaceutical Federation highlighting that services are 
most likely to advance in secondary and tertiary care set-
tings [3]. There are several likely contributory factors, 
including close multidisciplinary collaboration stimulating 
mutual trust and respect, ease of access to patient data and 
other key resources, peer support, leadership and aspects 
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of governance including role definition, education, training 
and continuing professional development. Tonna et al. [32] 
noted the importance of these factors in defining a guide 
to planning the implementation of pharmacist prescribing, 
an example of a clinical pharmacy service, in UK hospital 
practice.
Barriers for clinical pharmacy implementation in primary 
care such as lack of awareness of pharmacists’ skillset and 
their potential clinical roles were also reported in a qualita-
tive study in Canada [33]. The study highlighted that health-
care professionals were generally unaware of clinical phar-
macy roles, which subsequently affected implementation. 
Similar findings were also reported in relation to the com-
munity setting. For instance, a systematic review of factors 
influencing national implementation of innovations within 
community pharmacy described three key influences which 
are: pharmacy staff engagement with the proposed services, 
operationalisation of the innovations (including design, com-
plexity and resources needed), and pharmacy staff relation-
ships with patients and other healthcare professionals [34]. 
Thus, there is a need to improve the provision of clinical 
pharmacy services in primary and community settings which 
should take into consideration theoretical frameworks, such 
as the CFIR, which highlight the importance of thorough 
development and the need for piloting and continuous evalu-
ation in order to ensure the successful implementation of any 
future clinical pharmacy roles [29].
Pharmacist role expansion was facilitated mainly by 
the perceived level of education, training, and motivation 
that pharmacists possess which can further enable them to 
provide more clinical services in the future (CFIR domain: 
characteristics of individuals). This could be attributed to the 
increased focus on developing pharmacists’ skills in Qatar 
highlighted in the National Vision and National Health 
Strategy and evidenced by the level of pharmacy education 
offered in the state, the rigorous accreditation, licensing and 
continuous education training pharmacists in Qatar must 
undergo [22]. Similar facilitators related to pharmacists’ 
characteristics, mainly their motivation and knowledge, 
were also reported in a qualitative study with health-system 
pharmacists and managers who experienced the implementa-
tion of clinical pharmacy services in Brazil, highlighting the 
importance of having a skilled workforce for the successful 
implementation of such roles [35].
Implementing more advanced clinical pharmacy services, 
such as the pharmacist-managed anticoagulation clinic, was 
noted to be met with some resistance that was quickly over-
come post-implementation. Zaidan et al. [36] also reported 
that physicians were more likely to accept new roles per-
formed by pharmacists if they had exposure to these contem-
porary pharmacy services. These findings were also reported 
in the UK when pharmacists advocated for a prescribing 
role in relation to physicians’ concerns around liability and 
pharmacists’ abilities to perform such a role [11]. These 
findings highlight the importance of the lived experiences 
and the need for thorough planning and involvement of key 
stakeholders which also constitutes a key domain of CFIR 
thus highlighting the need to use a theoretical framework in 
the early development of any new innovation.
Despite these advances in clinical pharmacy services 
in Qatar, interviewees noted that the lack of public under-
standing of pharmacists’ knowledge, training and services 
in general is a major barrier to further role development 
especially within community pharmacy setting where phar-
macists are considered to be drug dispensers (CFIR domain: 
outer setting). Low public or patient awareness of extended 
pharmacy services in the community pharmacy setting was 
also reported to be a common finding in the UK accord-
ing to a recent systematic review of the current research 
literature focusing on perspectives on existing and future 
community pharmacy services [37]. This was often related 
to lack of exposure or utilisation of community pharmacy 
services. Thus, there is a great need to improve the public’s 
awareness of the real extent of pharmacists’ knowledge and 
skillset as well as the different roles they perform in order 
to allow them to expand their clinical services. This was 
considered especially important in Qatar where pharmacists 
are advocating for more clinical roles including prescribing. 
Recent studies have shown that key health stakeholders sup-
ported implementation of pharmacist prescribing in Qatar if 
additional training was provided and more efforts were made 
to increase awareness of the different services pharmacists 
provide in order to overcome potential resistance [20, 38].
This was a theory-driven, qualitative study generat-
ing in-depth, rich data of stakeholders’ perceptions. Steps 
were taken to enhance the trustworthiness (credibility and 
dependability) of the research data and findings, including 
adopting appropriate, well-recognised research methods, 
encouraging interviewees to be frank and talk freely and 
use of different researchers to independently analyse data. 
The key limitations are that the research outcomes are per-
ceptions of stakeholders, rather than objective measures of 
service outcomes and that the findings may not be transfer-
able beyond Qatar.
Further research should focus on the systematic develop-
ment, implementation and evaluation of any future clinical 
pharmacy service development in Qatar.
Conclusion
Health-related stakeholders in Qatar have positive percep-
tions of current clinical pharmacy services and support the 
expansion of pharmacist’s roles. However, service devel-
opment needs to consider the issues of patient and public 
awareness and initially target hospital settings.
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